SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-022395
Filing Date
2021-11-09
Accepted
2021-11-09 07:25:45
Documents
13
Period of Report
2021-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20211109.htm   iXBRL 8-K 43608
2 EX-99.1 ex99111921.htm EX-99.1 17367
  Complete submission text file 0001628280-21-022395.txt   206573

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20211109.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20211109_lab.xml EX-101.LAB 24844
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20211109_pre.xml EX-101.PRE 13045
6 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20211109_htm.xml XML 11523
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 211389871
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences